Dr. Reddy's Laboratories Ltd.

350 articles with Dr. Reddy's Laboratories Ltd.

• Dr. Reddy's to release Q2 FY 20 results on November 1, 2019

  10/14/2019

  Dr. Reddy's Laboratories Ltd. will announce results for the second quarter ended September 30, 2019 on Friday, November 1, 2019 after the Board Meeting.

• Dr. Reddy’s Announces the Launch of Over-the-Counter, Store-Brand Equivalent of Prevacid® 24HR Capsules (Lansoprazole Delayed-Release Capsules USP, 15 mg) in the U.S. Market

  9/16/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Lansoprazole Delayed-Release Capsules USP, 15 mg, an over-the-counter (OTC) store-brand equivalent of Prevacid® 24HR Capsules, in the United States market, as approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories Announces the Launch of Fosaprepitant for Injection in the U.S. Market

  9/11/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Fosaprepitant for Injection, the therapeutic generic equivalent of EMEND® (fosaprepitant) for injection, approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories Limited to Present at the Morgan Stanley Annual Global Healthcare Conference

  9/6/2019

  Dr. Reddy’s Laboratories Ltd (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) announced that the Company will be presenting at the Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, September 10th, 2019, in New York City.

• Dr. Reddy's Laboratories announces the launch of Bupropion Hydrochloride Extended-Release Tablets, USP (SR) in the U.S. Market

  9/5/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Bupropion Hydrochloride Extended-Release Tablets, USP (SR), a therapeutically equivalent generic version of Zyban® (Bupropion Hydrochloride) Extended-Release Tablets, approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories Announces the Launch of Vigabatrin Powder for Oral Solution, USP in the U.S. Market

  8/20/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Vigabatrin Powder for Oral Solution, USP in 500 mg per packet, a therapeutic equivalent generic version of Sabril® (vigabatrin) Powder for Oral Solution, USP, approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories announces the launch of Versavo® (bevacizumab biosimilar) in India

  8/19/2019

  Dr. Reddy’s Laboratories Ltd. announced that it has launched Versavo®, a biosimilar of Roche’s Avastin® in India, indicated for the treatment of several types of cancers.

• Dr. Reddy's Laboratories announces the launch of Pregabalin Capsules in the U.S. Market

  7/30/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Pregabalin Capsules a therapeutic equivalent generic version of Lyrica® (pregabalin) Capsules approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy’s Q1 FY20 Financial Results

  7/29/2019

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter ended June 30, 2019 under International Financial Reporting Standards (IFRS).

• Dr. Reddy's Laboratories Announces the Launch of Ramelteon Tablets, in the U.S. Market

  7/23/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Ramelteon Tablets, 8 mg, a therapeutically equivalent generic version of Rozerem® (ramelteon, 8 mg) Tablets, approved by the U.S. Food and Drug Administration (USFDA).

• Upsher-Smith Laboratories Completes Acquisition Of Two Treatments For Acute Migraine In Adults

  7/20/2019

  Strategic Acquisition of Tosymra™ (sumatriptan) Nasal Spray and Zembrace® SymTouch® (sumatriptan) Injection Further Expands and Diversifies Company's Portfolio

• Dr. Reddy’s Laboratories announces closure of the transaction to divest ZEMBRACE® SYMTOUCH® and TOSYMRA™ to Upsher-Smith Laboratories, LLC

  7/20/2019

  Dr. Reddy’s Laboratories Limited, announces the closure of the transaction with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to the satisfactory completion of all customary closing conditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended.

• Dr. Reddy’s announces the launch of over-the-counter, store-brand equivalent of Allegra-D® 12 HR Allergy and Congestion Extended-Release Tablets (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) in the U.S. Market

  7/19/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Fexofenadine HCl 60 mg and Pseudoephedrine HCl 120 mg Extended-Release Tablets, USP, an over-the-counter (OTC) store-brand equivalent of Allegra-D® 12 HR Allergy and Congestion Extended-Release Tablets, in the United States market, as approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's to release Q1 FY 20 results on July 29, 2019

  7/10/2019

  Dr. Reddy's Laboratories Ltd. will announce results for the first quarter ended June 30, 2019 on Monday, July 29, 2019 after the Board Meeting.

• Dr. Reddy’s Announces the Launch of the Over-the-counter Store Brand Equivalent of Mucinex® D Extended Release Tablets in Two Strengths in the U.S. Market

  7/9/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of an over-the-counter (OTC) store-brand equivalent of Mucinex® D Extended Release Tablets in two strengths—Guaifenesin 600 mg and Pseudoephedrine HCl 60 mg, and Guaifenesin 1200 mg and Pseudoephedrine HCl 120 mg—in the United States market, as approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces First-to-market Launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial in the U.S. Market

  7/3/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial, a therapeutic equivalent generic version of Hemabate® injection, 250 mcg/mL, approved by the U.S. Food and Drug Administration.

• Dr. Reddy's Laboratories Announces the Launch of Tobramycin Inhalation Solution, USP in the U.S. Market

  6/25/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of TOBI® (tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories Announces the Launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules in the U.S. Market

  6/22/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules, a therapeutic equivalent generic version of Vitamin K1 (Phytonadione) Injectable Emulsion USP, 10 mg/ml, approved by the U.S. Food and Drug Administration.

• Dr. Reddy’s Laboratories Announces Entering into a Definitive Agreement to Sell Its Neurology Branded Products to Upsher-Smith Laboratories, LLC

  6/14/2019

  Dr. Reddy’s Laboratories Ltd. announces that it has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC, pursuant to which Dr. Reddy’s would sell its US and select territory rights for ZEMBRACE® SYMTOUCH® 3 mg and TOSYMRA™ 10 mg, which are commercialized through its wholly owned subsidiary, Promius Pharma, LLC.

• Upsher-Smith Laboratories Enters Into Agreement To Acquire Tosymra™ (sumatriptan nasal spray) And Zembrace® SymTouch® (sumatriptan injection)

  6/13/2019

  Strategic Acquisition Diversifies Company's Portfolio and Provides New Options for Migraine Patients